Perioperative Monitoring of Serum RalA Autoantibodies in the Patients Treated with Radical Surgery

2018 Fiscal Year Final Research Report

• Project/Area Number: 26462029
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Toho University
• Principal Investigator: KOIKE Junichi 東邦大学, 医学部, 准教授 (30339155)
• Co-Investigator(Kenkyū-buntansha): 島田 英昭 東邦大学, 医学部, 教授 (20292691) ; 牛込 充則 東邦大学, 医学部, 助教 (90408849) ; 鈴木 孝之 東邦大学, 医学部, 助教 (10385768)
• Project Period (FY): 2014-04-01 – 2019-03-31
• Keywords: RalA / p53 / 大腸癌 / 血清抗体 / 腫瘍マーカー

Outline of Final Research Achievements

【Background and Purpose】Anti-RalA-IgG antibodies appear in the serum of cancer patients from the early stages of carcinogenesis. This serum RalA-IgG antibody is developed as a novel biomarker.【Patients and Methods】Preoperative serum and resected specimen were analyzed in 289 patients with colorectal cancer.【Results】 The positive rate of serum RalA-IgG antibody was 14%. The positive rate increased as the stage progression, but the relevance to the prognosis was unclear. Serum antibodies were not correlated with CEA, CA19-9 nor p53 antibodies. Immunostaining of tissues showed a moderate correlation with serum antibody titer.【Conclusion】Serum RalA antibody in the patients with colorectal cancer seems to be useful.

Free Research Field

消化器外科学

Academic Significance and Societal Importance of the Research Achievements

既存の腫瘍マーカーであるCEA, CA19-9, p53抗体いずれの陰性である約４０％の大腸癌症例で一定の陽性率となることから、CEA,CA19-9,p53抗体のいずれとも独立している血清RALA抗体検査の意義がある。血液検査による大腸癌のスクリーニングに寄与するものと思われる。